Base de dados : MEDLINE
Pesquisa : D02.455.426.559.389.454.450 [Categoria DeCS]
Referências encontradas : 149 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 15 ir para página                         

  1 / 149 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25144248
[Au] Autor:Duboisset J; Matar G; Besson F; Ficheux D; Benichou E; Russier-Antoine I; Jonin Ch; Brevet PF
[Ad] Endereço:Institut Lumière Matière, ILM UMR CNRS 5306, Université Claude Bernard Lyon 1 , 10 Rue Ada Byron, 69622 Villeurbanne Cedex, France.
[Ti] Título:Second harmonic generation from tryptophan-rich short peptides: W(n)K(m) and gramicidin A.
[So] Source:J Phys Chem B;118(35):10413-8, 2014 Sep 04.
[Is] ISSN:1520-5207
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We report the first hyperpolarizability of a series of tryptophan-rich short peptides with the respective sequence KWK, KWWK, KWWWK, KWWKWWK, where W and K stand for tryptophan and lysine. The measurements were performed with the technique of hyper-Rayleigh scattering in the bulk of an aqueous Tris buffer solution at a pH of 8.5 and a salt concentration of 150 mM at the non-resonant fundamental wavelength of 784 nm. The first hyperpolarizability of the different peptides follows a simple additive model scaling with the number of tryptophan residues contained in the peptide. However, it appears that the first hyperpolarizability response of a single tryptophan residue in the peptide strongly differs from that of an isolated tryptophan. Hence, it is therefore demonstrated that the local environment of the tryptophan residues within the peptide strongly influences its nonlinear optical response. A comparison with the first hyperpolarizability of the natural peptide gramicidin A measured in trifluoroethanol (TFE) further confirms the key role of the local environment on the first hyperpolarizability of tryptophan residues in peptides.
[Mh] Termos MeSH primário: Gramicidina/química
Lisina/química
Peptídeos/química
Triptofano/química
[Mh] Termos MeSH secundário: Concentração de Íons de Hidrogênio
Ipodato/química
Modelos Moleculares
Dinâmica não Linear
Peptídeos/genética
Espalhamento de Radiação
Soluções
Solventes/química
Espectrometria de Fluorescência
Trifluoretanol/química
Trometamina/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Peptides); 0 (Solutions); 0 (Solvents); 023C2WHX2V (Tromethamine); 1405-97-6 (Gramicidin); 75-89-8 (Trifluoroethanol); 8DUH1N11BX (Tryptophan); F604ZKI910 (Ipodate); K3Z4F929H6 (Lysine)
[Em] Mês de entrada:1505
[Cu] Atualização por classe:140904
[Lr] Data última revisão:
140904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140822
[St] Status:MEDLINE
[do] DOI:10.1021/jp506416s


  2 / 149 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:17389703
[Au] Autor:Laurberg P; Vestergaard H; Nielsen S; Christensen SE; Seefeldt T; Helleberg K; Pedersen KM
[Ad] Endereço:Department of Endocrinology and Medicine, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark. peter.laurberg@rn.dk
[Ti] Título:Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases.
[So] Source:J Clin Endocrinol Metab;92(6):2149-56, 2007 Jun.
[Is] ISSN:0021-972X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CONTEXT: Graves' hyperthyroidism and multinodular toxic goiter lead to high serum T(3) compared with serum T(4). The source of this high T(3) has not been clarified. OBJECTIVE: Our objective was to assess the role of iodothyronine deiodinase type 1 (D1) and type 2 (D2) for T(3) production and to estimate the sources of T(3) in hyperthyroidism. DESIGN AND SETTING: The study was a prospective, randomized, open-labeled study in a secondary care setting. PATIENTS AND METHODS: Consecutive patients with hyperthyroidism caused by Graves' disease or by multinodular toxic goiter were randomized to be treated with high-dose propylthiouracil (PTU) to block D1, PTU plus KI, or PTU plus sodium ipodate to additionally block D2. T(3) and T(4) were measured in serum, and we estimated the sources of T(3). RESULTS: PTU reduced the T(3)/T(4) in serum to 47.7 +/- 2.5% (mean +/- sem) of the initial value on d 4 of therapy in patients with Graves' disease. The addition of KI to PTU led to a greater fall in T(3) and T(4), but the balance was unaltered. After PTU plus ipodate, T(3)/T(4) on d 4 was lower, 34.1 +/- 1.2% of the initial value. Similar variations were observed in patients with multinodular toxic goiter. Thus, the major source of the excess T(3) was D1-catalyzed T(4) deiodination, with a minor role for D2. It was estimated that the majority of this D1-catalyzed T(3) production takes place in the hyperactive thyroid gland. CONCLUSION: Although thyroidal T(3) contributes only around 20% of total T(3) production in normal individuals, this is much higher in patients with a hyperactive thyroid, ranging up to two thirds. The major part is produced from T(4) deiodinated in the thyroid.
[Mh] Termos MeSH primário: Antitireóideos/administração & dosagem
Hipertireoidismo/tratamento farmacológico
Hipertireoidismo/metabolismo
Iodeto Peroxidase/antagonistas & inibidores
Propiltiouracila/administração & dosagem
Tri-Iodotironina/sangue
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Quimioterapia Combinada
Feminino
Bócio Nodular/tratamento farmacológico
Bócio Nodular/metabolismo
Doença de Graves/tratamento farmacológico
Doença de Graves/metabolismo
Seres Humanos
Iodeto Peroxidase/metabolismo
Ipodato/administração & dosagem
Masculino
Meia-Idade
Estudos Prospectivos
Tiroxina/sangue
Resultado do Tratamento
Tri-Iodotironina/biossíntese
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antithyroid Agents); 06LU7C9H1V (Triiodothyronine); 721M9407IY (Propylthiouracil); EC 1.11.1.- (iodothyronine deiodinase type I); EC 1.11.1.- (iodothyronine deiodinase type II); EC 1.11.1.8 (Iodide Peroxidase); F604ZKI910 (Ipodate); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:0707
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:070329
[St] Status:MEDLINE


  3 / 149 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:12682620
[Au] Autor:Martinez DS; Chopra IJ
[Ad] Endereço:Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, UCLA Center for Health Sciences, Los Angeles, CA, USA.
[Ti] Título:Use of oral cholecystography agents in the treatment of hyperthyroidism of subacute thyroiditis.
[So] Source:Panminerva Med;45(1):53-7, 2003 Mar.
[Is] ISSN:0031-0808
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:AIM: In this study, we describe our experience in treating subacute thyroiditis patients with 2 OCAs (sodium ipodate and sodium iopanoate). METHODS: We studied 10 consecutive patients with subacute thyroiditis treated with 1 of the 2 oral cholecystography agents (OCAs). RESULTS: Hyperthyroidism was controlled and symptoms improved markedly in each case without any evidence of subsequent relapse of thyroiditis after withdrawal of OCAs. Three of the 10 patients had been treated previously with corticosteroids and had demonstrated relapse of thyroiditis and hyperthyroidism after tapering or withdrawal of steroids. We observed no side effects of treatment with OCAs. CONCLUSION: Our data suggest that OCAs are effective and safe agents for management of hyperthyroidism in patients with subacute thyroiditis, even when they have relapsed after treatment with corticosteroids.
[Mh] Termos MeSH primário: Meios de Contraste/administração & dosagem
Hipertireoidismo/tratamento farmacológico
Hipertireoidismo/etiologia
Ácido Iopanoico/análogos & derivados
Ácido Iopanoico/administração & dosagem
Ipodato/administração & dosagem
Tireoidite Subaguda/complicações
[Mh] Termos MeSH secundário: Doença Aguda
Administração Oral
Adulto
Idoso
Colecistografia
Feminino
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contrast Media); F604ZKI910 (Ipodate); FE9794P71J (Iopanoic Acid)
[Em] Mês de entrada:0307
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:030412
[St] Status:MEDLINE


  4 / 149 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9261010
[Au] Autor:Tomaski SM; Mahoney EM; Burgess LP; Raines KB; Bornemann M
[Ad] Endereço:Department of Surgery, Tripler Army Medical Center, Hawaii 96859-5000, U.S.A.
[Ti] Título:Sodium ipodate (oragrafin) in the preoperative preparation of Graves' hyperthyroidism.
[So] Source:Laryngoscope;107(8):1066-70, 1997 Aug.
[Is] ISSN:0023-852X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Fourteen Graves' hyperthyroid patients who had been prepared for surgery with sodium ipodate (SI) 500 mg orally twice daily for 3 days were retrospectively studied. SI was administered in combination with propylthiouracil (10 cases) and beta blockers (all cases), which had been previously initiated. Free serum thyroxine (T4) and total triiodothyronine (T3) concentrations were measured before and after SI therapy on the morning of surgery. SI treatment significantly reduced total T3 concentration from 445.9 to 193.4 ng/dL (P < 0.0001) and free T4 concentration from 3.874 to 2.800 ng/dL (P = 0.0003). Preoperatively, only one patient had persistent tachycardia, and intraoperatively this same patient required beta blockers. Blood loss was unremarkable or reduced (average blood loss, 121 mL). On clinical examination glands were firm with normal or somewhat decreased vascularity. On histologic study all glands demonstrated changes consistent with treated Graves' disease. Preoperative treatment with SI appears to be a safe and efficacious method of preparing hyperthyroid patients for surgery.
[Mh] Termos MeSH primário: Antitireóideos/uso terapêutico
Doença de Graves/cirurgia
Ipodato/uso terapêutico
Pré-Medicação
Tireoidectomia
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos beta/uso terapêutico
Adulto
Antitireóideos/farmacologia
Perda Sanguínea Cirúrgica
Feminino
Doença de Graves/sangue
Doença de Graves/tratamento farmacológico
Seres Humanos
Ipodato/farmacologia
Masculino
Cuidados Pré-Operatórios
Propiltiouracila/uso terapêutico
Estudos Retrospectivos
Glândula Tireoide/efeitos dos fármacos
Glândula Tireoide/patologia
Tireotropina/sangue
Tiroxina/sangue
Tri-Iodotironina/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 0 (Antithyroid Agents); 06LU7C9H1V (Triiodothyronine); 721M9407IY (Propylthiouracil); 9002-71-5 (Thyrotropin); F604ZKI910 (Ipodate); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:9709
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:970801
[St] Status:MEDLINE


  5 / 149 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9215413
[Au] Autor:Murray LA; Peterson ME
[Ad] Endereço:Department of Medicine, Animal Medical Center, New York, NY 10021, USA.
[Ti] Título:Ipodate treatment of hyperthyroidism in cats.
[So] Source:J Am Vet Med Assoc;211(1):63-7, 1997 Jul 01.
[Is] ISSN:0003-1488
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the efficacy and safety of ipodate in the treatment of hyperthyroidism in cats. DESIGN: Prospective case series. ANIMALS: 12 cats with hyperthyroidism treated at The Animal Medical Center between November 1994 and March 1996. PROCEDURE: Each cat initially received 100 mg of ipodate/d, PO. The drug's effects on clinical signs, body weight, heart rate, and serum triiodothyronine (T3) and thyroxine concentrations were evaluated 2, 4, 6, 10, and 14 weeks after initiation of treatment. A CBC and serum biochemical analyses were performed at each evaluation to monitor potential adverse effects of the drug. Dosage of ipodate was increased to 150 mg/d and then to 200 mg/d at 2-week intervals if a good clinical response was not observed. RESULTS: 8 cats responded to treatment and 4 did not. Among cats that responded, mean body weight increased and mean heart rate and serum T3 concentration decreased during the study period. Among cats that did not respond, mean body weight decreased and mean heart rate and serum T3 concentration were not significantly changed. Serum thyroxine concentration remained high in all cats. Adverse clinical signs or hematologic abnormalities attributable to ipodate treatment were not reported in any of the cats. CLINICAL IMPLICATIONS: Ipodate may be a feasible alternative to methimazole for medical treatment of hyperthyroidism in cats, particularly those that cannot tolerate methimazole and are not candidates for surgery or radiotherapy. Cats with severe hyperthyroidism are less likely to respond to ipodate than are cats with mild or moderate disease, and cats in which serum T3 concentration does not return to the reference range are unlikely to have an adequate improvement in clinical signs.
[Mh] Termos MeSH primário: Doenças do Gato/tratamento farmacológico
Meios de Contraste/uso terapêutico
Hipertireoidismo/veterinária
Ipodato/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Gatos
Feminino
Frequência Cardíaca
Hipertireoidismo/tratamento farmacológico
Masculino
Estudos Prospectivos
Tiroxina/sangue
Tri-Iodotironina/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contrast Media); 06LU7C9H1V (Triiodothyronine); F604ZKI910 (Ipodate); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:9710
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:970701
[St] Status:MEDLINE


  6 / 149 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8952775
[Au] Autor:Mariani R; Bertrand AM; Maillotte AM; Peyrade C; Bortoluzzi MN
[Ad] Endereço:Service de pédiatrie, hôpital de Cimiez, Nice, France.
[Ti] Título:[Treatment of neonatal hyperthyroidism with calcium iopodate].
[Ti] Título:Traitement de l'hyperthyroïdie néonatale par l'iopodate de calcium..
[So] Source:Arch Pediatr;3(11):1102-6, 1996 Nov.
[Is] ISSN:0929-693X
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:BACKGROUND: Treatment of hyperthyroidism in those neonates born to mothers with Grave's disease is difficult. Calcium ipodate, an agent for oral cholecystography, inhibits extra-thyroid conversion of T3 to T4 and diminishes thyroid secretion. CASE REPORTS: Two neonates with clinical manifestations and biological findings of hyperthyroidism were given calcium ipodate orally, 400 mg every 3 days, from day 26 to 50 for the first patient and from day 9 to 18 for the second in association with a beta blocker. Clinical manifestations disappeared within 2 days and circulating levels of T3 and T4 were normalized within 2-5 days. CONCLUSIONS: This treatment was effective and well-tolerated in both patients and in three others previously reported; it should be confirmed in a larger number of patients and controlled by measuring levels of antibodies directed against thyrotropin-releasing hormone receptors in order to avoid relapse after cessation of treatment as seen in our second patient.
[Mh] Termos MeSH primário: Hipertireoidismo/tratamento farmacológico
Ipodato/uso terapêutico
Tri-Iodotironina/antagonistas & inibidores
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos beta/administração & dosagem
Antagonistas Adrenérgicos beta/uso terapêutico
Quimioterapia Combinada
Feminino
Seres Humanos
Recém-Nascido
Ipodato/administração & dosagem
Propranolol
[Pt] Tipo de publicação:CASE REPORTS; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 06LU7C9H1V (Triiodothyronine); 9Y8NXQ24VQ (Propranolol); F604ZKI910 (Ipodate)
[Em] Mês de entrada:9701
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:961101
[St] Status:MEDLINE


  7 / 149 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8694676
[Au] Autor:Arem R; Munipalli B
[Ad] Endereço:Department of Medicine, Baylor College of Medicine, Houston, Tex., USA.
[Ti] Título:Ipodate therapy in patients with severe destruction-induced thyrotoxicosis.
[So] Source:Arch Intern Med;156(15):1752-7, 1996 Aug 12-26.
[Is] ISSN:0003-9926
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We describe 4 patients with severe destruction-induced thyrotoxicosis who had a rapid clinical response to oral sodium ipodate (500 mg daily). The underlying thyroid disorders in the patients were postpartum thyroiditis, subacute thyroiditis, silent thyroiditis, and radiation-induced thyroiditis. Ipodate therapy was given for 6 to 10 weeks until restoration of thyroid function to normal. In all patients, an almost complete resolution of symptoms occurred by the third day of ipodate treatment. In the patient with radiation thyroiditis, a daily clinical score of thyrotoxicosis declined within 2 to 3 days. The score remained low as long as the patient was receiving ipodate, but 2 attempts to discontinue ipodate therapy while thyroxine levels were elevated resulted in a rise of the thyrotoxicosis clinical score. This suggests that ipodate therapy, by rapidly reducing triiodothyronine levels through inhibition of the 5' monodeiodination and blockage of the peripheral effects of thyroid hormone, controls severe thyrotoxicosis mediated by destruction and should be considered in this setting in conjunction with beta-adrenergic blockade.
[Mh] Termos MeSH primário: Meios de Contraste/uso terapêutico
Ipodato/uso terapêutico
Tireotoxicose/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Feminino
Seres Humanos
Masculino
Meia-Idade
Índice de Gravidade de Doença
Hormônios Tireóideos/sangue
Tireotoxicose/sangue
Tireotoxicose/etiologia
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contrast Media); 0 (Thyroid Hormones); F604ZKI910 (Ipodate)
[Em] Mês de entrada:9608
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:960812
[St] Status:MEDLINE


  8 / 149 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:7608275
[Au] Autor:Chopra IJ; van Herle AJ; Korenman SG; Viosca S; Younai S
[Ad] Endereço:Department of Medicine, University of California Center for the Health Sciences, Los Angeles 90024, USA.
[Ti] Título:Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis.
[So] Source:J Clin Endocrinol Metab;80(7):2178-80, 1995 Jul.
[Is] ISSN:0021-972X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Five hyperthyroid patients (two men and three women) with typical features of subacute thyroiditis were treated with sodium ipodate (Oragrafin; 0.5 g, orally daily or every other day) for 15-60 days; the treatment was stopped when both serum T4 and T3 levels were normal. All patients studied demonstrated a prompt normalization of serum T3, improvement in clinical symptoms of hyperthyroidism, and/or weight gain. We observed no side-effects of treatment with sodium ipodate. Our data suggest that sodium ipodate is a safe and effective agent for management of hyperthyroidism in subacute thyroiditis.
[Mh] Termos MeSH primário: Hipertireoidismo/tratamento farmacológico
Ipodato/uso terapêutico
Tireoidite Subaguda/tratamento farmacológico
Tireotropina/sangue
Tiroxina/sangue
Tri-Iodotironina/sangue
[Mh] Termos MeSH secundário: Adulto
Autoanticorpos/sangue
Peso Corporal/efeitos dos fármacos
Feminino
Seguimentos
Seres Humanos
Hipertireoidismo/sangue
Hipertireoidismo/etiologia
Masculino
Meia-Idade
Glândula Tireoide/imunologia
Glândula Tireoide/metabolismo
Tireoidite Subaguda/sangue
Tireoidite Subaguda/imunologia
Fatores de Tempo
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Autoantibodies); 06LU7C9H1V (Triiodothyronine); 9002-71-5 (Thyrotropin); F604ZKI910 (Ipodate); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:9508
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:950701
[St] Status:MEDLINE


  9 / 149 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8035306
[Au] Autor:Gordon JT; Tomlinson EE; Greenberg J; Dratman MB
[Ad] Endereço:Department of Psychiatry, University of Pennsylvania, Philadelphia.
[Ti] Título:An acute dose of desmethylimipramine inhibits brain uptake of [125I]3,3',5-triiodothyronine (T3) in thyroxine-induced but not T3-induced hyperthyroid rats: implications for tricyclic antidepressant therapy.
[So] Source:J Pharmacol Exp Ther;270(1):111-7, 1994 Jul.
[Is] ISSN:0022-3565
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The tricyclic antidepressant, desmethylimipramine (DMI), a highly selective inhibitor of presynaptic uptake of norepinephrine (NE), has also been shown to reduce [125I]3,3',5-triiodothyronine (T3) uptake in rat brain synaptosomes. Using DMI as a probe to examine 1) possible noradrenergic influences on thyroid hormone (TH) actions in brain and 2) TH:affective disorder relationships, we found that a single dose of DMI produces a small (7.4-25%) but significant (P < or = .05) decrease in brain uptake of both labeled T3 (T3) and labeled thyroxine (T4) across the spectrum of thyroid states from hypothyroid (HYPO) to euthyroid to T4-induced hyperthyroid. Therefore, it was noted with considerable interest that DMI appeared not to interfere with brain T3 uptake in T3-induced hyperthyroid (T3-HYPER) rats. To confirm this finding, thyroidectomized male rats were made T3-HYPER through administration of T3 (20 micrograms/kg) for 3 weeks or maintained without TH supplement for 6 weeks, becoming HYPO. Rats were given i.v. T3 and 5 min later i.p. DMI or saline. They were decapitated at 3 hr and brains retrieved for radiochemical analysis. Each experiment was run in three separate trials, with three to four rats in each treatment category (DMI or saline). Evaluation by analysis of variance showed that T3 concentrations (percentage of dose) were significantly lower in DMI than in saline-treated rat brain for HYPO (-15%; P = .0034) but not T3-HYPER rats (-2%; P = .6595). These results suggest that, as it does in the case of NE, DMI tends to block TH uptake sites in rat brain. The data also demonstrate a differential affinity for those sites in which T3 > DMI > T4 and suggest that T3 might augment tricyclic antidepressant therapy more effectively than T4.
[Mh] Termos MeSH primário: Antidepressivos Tricíclicos/uso terapêutico
Encéfalo/efeitos dos fármacos
Encéfalo/metabolismo
Desipramina/farmacologia
Hipertireoidismo/metabolismo
Tiroxina/farmacologia
Tri-Iodotironina/farmacocinética
[Mh] Termos MeSH secundário: Análise de Variância
Animais
Encéfalo/enzimologia
Relação Dose-Resposta a Droga
Hipertireoidismo/induzido quimicamente
Hipertireoidismo/tratamento farmacológico
Hipotireoidismo/tratamento farmacológico
Hipotireoidismo/metabolismo
Iodeto Peroxidase/antagonistas & inibidores
Radioisótopos do Iodo
Ipodato/farmacologia
Masculino
Ratos
Ratos Sprague-Dawley
Tiroxina/farmacocinética
Fatores de Tempo
Tri-Iodotironina/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Antidepressive Agents, Tricyclic); 0 (Iodine Radioisotopes); 06LU7C9H1V (Triiodothyronine); EC 1.11.1.8 (Iodide Peroxidase); F604ZKI910 (Ipodate); Q51BO43MG4 (Thyroxine); TG537D343B (Desipramine)
[Em] Mês de entrada:9408
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:940701
[St] Status:MEDLINE


  10 / 149 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:8487661
[Au] Autor:Roti E; Gardini E; Minelli R; Bianconi L; Braverman LE
[Ad] Endereço:Cattedra di Endocrinologia, Universitá di Parma, Italy.
[Ti] Título:Sodium ipodate and methimazole in the long-term treatment of hyperthyroid Graves' disease.
[So] Source:Metabolism;42(4):403-8, 1993 Apr.
[Is] ISSN:0026-0495
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A prospective study was conducted to evaluate the effect of prolonged treatment of hyperthryoid Graves' disease with methimazole (MMI) for 12 months or Na ipodate for only 6.6 +/- 1.1 months, since the drug had to be discontinued because of persistent or recurrent hyperthyroidism during treatment. The eight patients who were treated with MMI alone for 12 months became euthyroid, and seven remained in remission for at least 6 months after MMI was discontinued. In contrast, only two of 10 patients treated with Na ipodate alone became euthyroid and remained so during therapy. No ipodate was discontinued in the eight patients who did not respond, and they were then treated with MMI. One patient had recurrent hyperthyrodism after NA ipodate was discontinued, and she was then treated with MMI. MMI was efficacious in treating these nine patients, and all patients were euthyroid by the third month of MMI administration. Five of these nine patients remained euthyroid for at least 6 months after MMI was discontinued, a remission rate that was not significantly different from that observed in the eight patients treated only and initially with MMI (Fisher's Exact Test). There was no significant change in serum thyroid peroxidase antibodies during treatment with MMI alone, Na ipodate alone, or Na ipodate followed by MMI.(ABSTRACT TRUNCATED AT 250 WORDS)
[Mh] Termos MeSH primário: Doença de Graves/tratamento farmacológico
Ipodato/uso terapêutico
Metimazol/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Autoanticorpos/sangue
Peso Corporal
Feminino
Doença de Graves/sangue
Frequência Cardíaca
Seres Humanos
Ipodato/administração & dosagem
Masculino
Metimazol/administração & dosagem
Estudos Prospectivos
Glândula Tireoide/fisiopatologia
Tireotropina/sangue
Tiroxina/sangue
Tri-Iodotironina/sangue
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Autoantibodies); 0 (thyroid microsomal antibodies); 06LU7C9H1V (Triiodothyronine); 554Z48XN5E (Methimazole); 9002-71-5 (Thyrotropin); F604ZKI910 (Ipodate); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:9306
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:930401
[St] Status:MEDLINE



página 1 de 15 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde